Suprachoroidal Administration In Subjects With Metastases To The Choroid

Overview

About this study

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary carcinoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.
* Have at least one Metastases to the Choroid in the study eye

Exclusion Criteria:

* Active ocular infection or disease.
* Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.
* Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/10/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lauren Dalvin

Contact us for the latest status

Contact information:

Suzanne Wernimont

(507) 538-8119

wernimont.suzanne@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597991

Mayo Clinic Footer